Rondo Therapeutics, founded in 2021 and headquartered in Hayward, California, focuses on developing novel bispecific antibodies to combat cancer. The company's core mission is to harness the immune system to safely target and eliminate tumors, specifically solid tumors, while maximizing efficacy and minimizing side effects. Rondo Therapeutics aims to revolutionize cancer treatment through its innovative approach to immune-cell engaging bispecific antibodies.
The company is supported by top investors and guided by a dynamic team of seasoned entrepreneurs, exceptional scientists, and industry-leading advisors. Rondo Therapeutics has made significant strides in its pipeline development, positioning itself as a promising player in the oncology sector. Its impact lies in its potential to offer more effective and safer cancer therapies, contributing to the advancement of immuno-oncology.
